Team Fundraising Goal: $250,000
$235,558.16
Team Fundraising Goal: $250,000
$235,558.16
Quick Info
- Winter Season KICKOFF! - 07/24/10
- FINAL Coaches' Email NEW [06/25]
- Personalize Your Webpage!
- Write a Good Letter
- Donor Form - Include with your letters
- Supplemental Fundraising Packet
- Where to Send Your Checks
LLS funds more blood cancer research than any other voluntary health agency. Many LLS-supported advances help beyond the blood cancer patients for whom they were first developed.
LLS support was instrumental in the development of Velcade®, the targeted treatment for patients with multiple myeloma, now also approved for mantle cell lymphoma.
LLS-funded researchers discovered the value of combining Rituxan® with standard chemotherapy resulting in the first survival rate improvement in 25 years for patients with diffuse large B-cell lymphoma.
An LLS funded researcher developed Gleevec®, a pill for chronic myelogenous leukemia (CML). Now, 95% of newly diagnosed, chronic-phase CML, patients survive more than five years with good quality of life.
Recent Photos
Your Honored Teammates
Tyler CordovaDiagnosis: Non-Hodgkins Lymphoma & Leukemia
Diagnosed: March 2007
Virginia GarnerDiagnosis: Chronic Myelogenous Leukemia (CML)
Diagnosed: August 1997
Roger KlinkhartDiagnosis: Chronic Lymphocytic Leukemia (CLL)
Diagnosed: February, 2003
Diane WentworthDiagnosis: Chronic Lymphocytic Leukemia (CLL)
Diagnosed:November 2008
tell us your story: click here
Events & Important Dates
- Winter Season KICKOFF! - 07/24/10: www.sgvtnt.com/winter